Journey Medical Corp Files 8-K on Financials

Ticker: DERM · Form: 8-K · Filed: Mar 26, 2025 · CIK: 1867066

Sentiment: neutral

Topics: financial-reporting, operations

Related Tickers: JMEI

TL;DR

JMEI filed an 8-K on 3/26/25 detailing financial results and operations.

AI Summary

Journey Medical Corporation filed an 8-K on March 26, 2025, reporting on its results of operations and financial condition, and filing financial statements and exhibits. The filing details the company's corporate information, including its incorporation in Delaware and principal executive offices in Scottsdale, Arizona.

Why It Matters

This 8-K filing provides an update on Journey Medical Corporation's financial condition and operations, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate material adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Journey Medical Corporation's results of operations and financial condition, and to file financial statements and exhibits.

When was this 8-K filing submitted?

This 8-K filing was submitted on March 26, 2025.

In which state is Journey Medical Corporation incorporated?

Journey Medical Corporation is incorporated in Delaware.

Where are Journey Medical Corporation's principal executive offices located?

Journey Medical Corporation's principal executive offices are located at 9237 E Via de Ventura Blvd., Suite 105, Scottsdale, AZ 85258.

What is the SIC code for Journey Medical Corporation?

The Standard Industrial Classification (SIC) code for Journey Medical Corporation is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 26, 2025 regarding Journey Medical Corp (DERM).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing